PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number** 10/723 142 Filing Date TRANSMITTAL November 25, 2003 First Named Inventor Roth, Richard **FORM** Art Unit 1623 **Examiner Name** SAKELARIS, Sally A. (to be used for all correspondence after initial filing) Attorney Docket Number SEQ-4065-UT Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Drawing(s) Fee Transmittal Form Appeal Communication to Board Licensing-related Papers of Appeals and Interferences Fee Attached Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Petition Amendment/Reply Petition to Convert to a Proprietary Information After Final Provisional Application Power of Attorney, Revocation Status Letter Change of Correspondence Address Affidavits/declaration(s) Other Enclosure(s) (please Identify **Terminal Disclaimer** below): **Extension of Time Request** Request for Refund **Express Abandonment Request** CD, Number of CD(s)_ Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) SB08 - 1 page cover letter - 2 pages Reply to Missing Parts/ return post card - 1 page Incomplete Application transmittal form in duplicate - 2pages Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name BioTechnology Law Group Signature Printed name Bruce Grant Reg. No. Date 47,608 PA SEPT. Zous **CERTIFICATE OF TRANSMISSION/MAILING** I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Bruce Grant

Typed or printed name

Date

K FEPT. 2800

Examiner: SAKELARIS, Sally A.

Group Art Unit: 1623

Docket: SEQ-4065-UT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Serial No.: ROTH et al

10/723,142

Filed: Title:

November 25, 2003

METHODS FOR IDENTIFYING RISK OF BREAST CANCER AND

TREATMENTS THEREOF

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir/Madam,

In compliance with the duty under 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 et. seq., the enclosed materials are brought to the Examiner's attention for consideration in connection with the above-identified patent application. Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form SB08A be considered by the Examiner and made of record. Pursuant to MPEP 609, Applicants request that a copy of the SB08A form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication. Applicants also bring to the Examiner's attention the existance of the following co-pending related applications: (1) application no. 10/723,670 (Attorney Docket: SEQ-4067-UT), filed November 25, 2003, (2) application no. 10/723,518 (Attorney Docket: SEQ-4068-UT), filed November 25, 2003, (3) application no. 10/723,681 (Attorney Docket: SEQ-4069-UT), filed November 25, 2003, (4) application no. 10/857,780 (Attorney Docket: SEQ-4069-CP), filed May 27, 2004, (5) application no. 10/722,939 (Attorney Docket: SEQ-4071-UT), filed November 25, 2003, and (6) application no. 10/723,683 (Attorney Docket: SEQ-4072-UT), filed November 25, 2003.

Serial No.: 10/723,142

Filing Date: November 25, 2003

Title: METHODS FOR IDENTIFYING RISK OF BREAST CANCER AND TREATMENTS THEREOF

Page 2 Dkt: SEQ-4065-UT

The listed documents are being submitted in compliance with 37 CFR § 1.97(b), before the mailing date of the first office action on the merits. Accordingly, it is respectfully submitted no fees are due.

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

BioTechnology Law Group 658 Marsolan Ave.

Solana Beach, CA 92075 Telephone: (858) 623-9470

Fax: (858) 623-9476

Email: bruce@biotechnologylawgroup.com

PTO/SB/08A(08-03)
Approved for use through 07/31/2009. OMB 0951-0031
US Patient & Trademerk Office: U.S. DEPARTMENT OF COMMERCE
of information unless it contains a velid OMB control number.

Substitute (65/m 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known	quied to respond to a consector of finormation amoss it contains a valid condition number.
Application Number	10/723,142
Filing Date	November 25, 2003
First Named Inventor	Roth, Richard
Group Art Unit	1623
Examiner Name	SAKELARIS, Sally A.
Attorney Docket No: S	EQ-4065-UT

Sheet 1 of 1

Cuambas:	0:4	LUCD Decument Number		DOCUMENTS	
Examiner initials *	Cite No. ¹	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines,Where Relevant Passages or Relevant Figures Appear
	A1.	US 5,547,835	Aug-96	Koster	
	A2.	US 5,605,798	Feb-97	Koster	
	A3.	US 5,691,141	Nov-97	Koster	
	A4.	US 5,849,542	Dec-98	Reeve et al.	
	A5.	US 5,869,242	Feb-99	Kamb	
	A6.	US 5,928,906	Jul-99	Koster et al.	
	A7.	US 6,043,031	Mar-00	Koster et al.	
	A8.	US 6,194,144	Feb-01	Koster	Val - 70 del 1 1 1
	A9.	US 6,258,538	Jul-01	Koster et al.	
	A10.				

		FORE	IGN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines, Where Relevant Passages or Relevant Figures Appear	T²
	A11.					

	OTHE	ER DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	A12.	Elbashir et al., Methods 26(2):199-213 (2002)	
	A13.	Forbes, Seminars in Oncology, 24(1)Suppl.1:S1-20 - S1-35 (1997)	
	A14.	Ford et al., British J. Cancer, 72:805-812 (1995)	
	A15.	French et al., British J. Cancer, 87:1034-1041 (2002)	1
	A16.	Miki et al., Science, 266:66-71 (1994)	1
	A17.	Wooster et al., Science, 265:2088-2090 (1994)	† ·

EXAMINER

DATE CONSIDERED